1. Chronic nonbacterial osteomyelitis in children: a multicenter case series.
- Author
-
Concha S, Hernández-Ojeda A, Contreras O, Mendez C, Talesnik E, and Borzutzky A
- Subjects
- Adalimumab therapeutic use, Adolescent, Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Antibodies, Antinuclear immunology, Arthritis, Juvenile drug therapy, Bone Density Conservation Agents therapeutic use, Child, Child, Preschool, Chile epidemiology, Comorbidity, Delayed Diagnosis, Diphosphonates therapeutic use, Erythema Nodosum epidemiology, Female, Glucocorticoids therapeutic use, HLA-B27 Antigen genetics, Humans, Male, Methotrexate therapeutic use, Osteomyelitis diagnosis, Osteomyelitis drug therapy, Osteomyelitis physiopathology, Remission Induction, Treatment Outcome, Uveitis epidemiology, Antirheumatic Agents therapeutic use, Arthritis, Juvenile epidemiology, Osteomyelitis epidemiology
- Abstract
Chronic nonbacterial osteomyelitis (CNO) is a primary autoinflammatory bone disease that presents more frequently in children and is characterized by inflammatory bone lesions in the absence of an infectious etiology. There is little information of this disease in Latin America. The objective of the study was to evaluate demographic, clinical, laboratory, imaging, histopathology characteristics, and treatment responses of pediatric CNO patients. The clinical records of 19 patients with CNO diagnosed between 2007 and 2019 at three tertiary centers in Santiago, Chile were reviewed. The median age of onset was 10 years and 47% were female. Median delay in diagnosis was 12 months. All patients had a pattern of recurrent multifocal disease. 37% of patients had positive antinuclear antibodies and 16% HLA-B27 positivity. 21% of patients presented arthritis or other rheumatologic comorbidity, although no association with psoriasis, inflammatory bowel disease (IBD) or palmoplantar pustulosis (PPP) was observed. Eighteen patients received treatment with nonsteroidal anti-inflammatory drugs with partial response. Twelve patients received methotrexate, and half of them received steroids at the same time reaching remission in 50%. Of the five patients who received bisphosphonates, 60% achieved remission. All four patients who received adalimumab had comorbid arthritis and 75% achieved remission. In a series of Chilean children with CNO, all patients presented with multifocal lesions. Comorbid autoimmune diseases including arthritis were frequent, but no association was observed with psoriasis, IBD, or PPP.
- Published
- 2020
- Full Text
- View/download PDF